Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
43M
-
Shares change
-
+4.88M
-
Total reported value, excl. options
-
$867M
-
Value change
-
+$98.8M
-
Put/Call ratio
-
4.21
-
Number of buys
-
85
-
Number of sells
-
-29
-
Price
-
$20.16
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q4 2020
136 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q4 2020.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43M shares
of 61.4M outstanding shares and own 70.08% of the company stock.
Largest 10 shareholders include FMR LLC (6.45M shares), BVF INC/IL (4.27M shares), RTW INVESTMENTS, LP (3.65M shares), Consonance Capital Management LP (2.73M shares), BlackRock Inc. (2.59M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), FARALLON CAPITAL MANAGEMENT LLC (2.43M shares), VANGUARD GROUP INC (2.02M shares), STATE STREET CORP (1.48M shares), and BAKER BROS. ADVISORS LP (1.44M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.